The Physiology of Amylin and Insulin

Abstract

Glucose homeostasis is accomplished through intricate, and arguably, elegant interactions among several organs and hormones. Historically, glucose homeostasis has been viewed somewhat narrowly-insulin from pancreatic β cells regulated glucose disposal, while glucagon from pancreatic β cells regulated glucose appearance during fasting states. But more recent characterization and understanding of the role of incretin hormones from the gut-notably, glucagon-like peptide 1 and gastric inhibitory polypeptide-and amylin from pancreatic β cells has led to a more complete model of glucose homeostasis. Furthermore, availability of pharmacologic agents to replace, mimic, or enhance the actions of these hormones allows application of this more complete model of glucose homeostasis to the treatment of type 1 and type 2 diabetes. This article provides an overview of the role of the pancreatic hormone amylin in glucose homeostasis and of Pramlintide, a analogue of native amylin, recently approved as adjunct therapy to insulin in people with type 1 and type 2 diabetes.

Get full access to this article

View all access options for this article.

References

Pehling G

Tessari P

Gerich JE

Haymond MW

Service FJ

Rizza RA

. Abnormal meal carbohydrate disposition in insulin-dependent diabetes: relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest. 1984;74:985-991.

Unger RH

Foster DW

. Diabetes mellitus. In:

Wilson JD

Foster DW

, eds. Williams Textbook of Endocrinology. 8th ed.Philadelphia, Pa: W. B. Saunders; 1992:1255-1333.

Kruger DF

Gatcomb PM

Owen SK

. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25:389-397.

Weyer C

Maggs DG

Young AA

Kolterman OG

. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001;7:1353-1373.

Unger RH

. Glucagon physiology and pathophysiology. N Engl J Med. 1971;285:443-449.

Wahren J

Felig P

Hagenfeldt L

. Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest. 1976;57:987-999.

Frank JW

Saslow SB

Camilleri M

Thomforde GM

Dinneen S

Rizza RA

. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology. 1995;109:755-765.

Fineman MS

Koda JE

Shen LZ

et al.

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002;51:636-641.

Fineman M

Weyer C

Maggs DG

Strobel S

Kolterman OG

. The human amylin analog, pramlintide, reduces postprandial hyper-glucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34:504-508.

10.

Rayner CK

Samsom M

Jones KL

Horowitz M

. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24:371-381.

11.

Kong MF

Stubbs TA

King P

et al.

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia. 1998;41:577-583.

12.

Kolterman OG

Schwartz S

Corder C

et al.

Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia. 1996;39:492-499.

13.

Thompson RG

Gottlieb A

Organ K

Koda J

Kisicki J

Kolterman OG

. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med. 1997;14:547-555.